Radiotherapy of cancer has been a subject to get significant notice for clinical and research interest after the discovery of neutron. For instance, radiotherapy using fast neutron beam for the destruction of tumors cell is emerging as a promising technique on the basis of recent research data. Nowadays, neutron capture therapy (NCT) which is a somewhat different form of neutron-based therapy proposed by Locher in 1936 and particularly for intracranial tumors is proposed by Sweet in 1951.
In NCT, a neutron captured agent called yielding boron NCT has been guided into the malignant tissue, and after that, at a suitable time, the boron NCT is exposed by thermal neutrons generated by either an external neutron beam producer or a suitable nuclear-based accelerator. These thermal or high energetic neutrons interact with the boron NCT, which is actually present inside the malignant cells and generates highly energetic alpha particles and lithium ions within the cells which leads to their destruction by damaging its DNA itself.
Source: https://sgtuniversity.ac.in/blogs/use-of-physics-and-biophysics-in-cancer-treatment/
Chemotherapy drugs are medicines used to treat cancer.
These drugs either kill or prevent the growth and division of cancer cells.
Chemotherapy treatment may be given before or after surgery, or to boost radiotherapy.
In advanced cancer, chemotherapy is used to stop and slow down the spread of cancer.
Additionally, the growing adoption of radiotherapy procedures for cancer treatment, increasing use of particle therapy for cancer treatment, and the rising number of conferences and symposia focusing on the advancements in radiotherapy are some of the other major factors driving the growth of this market.
What is the Expert Analysis about the Future Growth of Radiotherapy Market?
The radiotherapy market is projected to reach USD 7.0 billion by 2024 from USD 5.6 billion in 2018, at a CAGR of 4.1% Global Radiotherapy Market Opportunities: The emerging markets, growing government and private investments to meet the increasing demand for cancer treatment, and the improving reimbursement scenario are expected to present a wide range of growth opportunities for market players.
Download PDF Brochure Now: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=567 Global Market Segmentation: Based on application, the external beam radiotherapy market is segmented into prostate cancer, breast cancer, lung cancer, head & neck cancer, colorectal cancer, and other cancers.
Based on type, the external beam radiotherapy market is classified into IGRT, IMRT, stereotactic therapy, particle beam therapy, and 3D-CRT.
Advancements in the field of particle beam therapy (such as PBS) and increasing research activities in the field of radiation oncology using proton therapy systems are the key factors driving the growth of this segment.
The relatively new technology for integrating magnetic resonance imaging (MRI) with radiation therapy is becoming increasingly prevalent, with revenues from the MRI-guided radiation therapy systems market exceeding US$ 220 Mn in 2018, according to a recent study by Fact.MR.
This remarkable growth potential of the MRI-guided radiation therapy systems market can be attributed to burgeoning adoption of innovative technologies in the cancer diagnosis & treatment, alongside growing focus on patient-centric care.
The study offers comprehensive outlook of the MRI-guided radiation therapy systems market for the period, 2018 to 2028.
The MRI-guided radiation therapy systems market is projected to record a CAGR of approximately 20% through 2028.The MRI-guided radiation therapy systems market report includes global as well as emerging players:Elekta ABVIEWRAY TECHNOLOGIES, INC.Device Technologies Australia Pty Ltd.OthersThe study assesses macro and microeconomic factors that define the growth prospects of the MRI-guided radiation therapy systems market.
It finds that leading players in the rapidly-growing healthcare sector are vying for new techniques in cancer treatment to compensate for involuntary patient movements and improve precision to a much higher degree.
In addition, the paradigm shift in preference of cancer patients towards radiation therapies, from invasive to non-invasive procedures, is expected to remain instrumental in adoption of MRI-guided radiation therapy systems in cancer care.Hospitals Remain the Target Customers for Market PlayersThe study opines that hospital, with over 51% revenue share, will remain the target customer for players in the MRI-guided radiation therapy systems market in 2019.
